Navigation Links
Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
Date:7/29/2013

NANJING, China, July 29, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2013 on Tuesday, August 13, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, August 13 at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll: +65.6723.9381United States toll-free: +1.866.519.4004United States toll: +1.845.675.0437China Domestic toll: 800.819.0121 China Domestic mobile toll: 400.620.8038 Hong Kong toll: +852.2475.0994Please ask to be connected to Q2 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 23263347. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free: +1. 855.452.5696United States toll: +1. 646.254.3697 The passcode for replay participants is 23263347. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:
Jie Liu D'Elia
Vice President
Simcere Pharmaceutical Group

Tel: 86-25-8556-6666*8857

 

In Beijing:
Yue Yu

Brunswick Group

Tel: 86-10-5960-8600 In the United States:Cindy Zheng

Brunswick Group

Tel: 1-212-333-3810

 

 

 


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
2. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
3. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
5. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
6. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
7. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
8. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
9. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
10. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
11. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Ore. , May 3, 2016   ... medical technology, today announced Food and Drug Administration ... resynchronization defibrillator that provides heart failure patients with ... Iperia devices also have remote monitoring with daily ... adapts the heart rate in response to physiological ...
(Date:5/3/2016)... According to market research "Global ... and Demand Forecast to 2022 - Industry Insights by ... Very High Field, Low to Mid Field, and Ultra ... Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" ... market was valued at $5,351.7 million in 2015, and ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... ... online university, has announced today the launch of its Associates and Bachelor's degrees ... President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; Chairman and CEO ...
(Date:5/3/2016)... ... 2016 , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) ... or rare procedures in an environment that looks and feels real. , Located in ... inventors and “hackers” to develop and test new devices or software platforms and see ...
(Date:5/3/2016)... Dallas, Texas (PRWEB) , ... May 03, 2016 , ... ... that live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, ... Oak Lawn/Uptown, Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park ...
(Date:5/3/2016)... ... May 03, 2016 , ... Intrigma, the leading provider ... Health is expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient Scheduler ... of concept. The Portland, Oregon based health system conducted a one-year pilot of ...
(Date:5/3/2016)... Hollywood, CA (PRWEB) , ... May 03, 2016 , ... ... special promotions on cosmetic dental treatments to both new and existing patients. Cosmetic dentistry ... great option for patients who have healthy smiles with some minor or more serious ...
Breaking Medicine News(10 mins):